[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ct-angiography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ct-angiography":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,69,98,127,154,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643993","correlation-between-ct-pulmonary-angiography-metrics-and-right-heart-catheterization-parameters-in-pre-capillary-pulmonary-hypertension-100643993",false,"NCT07667595","Correlation Between CT Pulmonary Angiography Metrics and Right Heart Catheterization Parameters in Pre-Capillary Pulmonary Hypertension","Inclusion Criteria:\n\n1-Age ≥ 18 years at time of enrolment. 2-Confirmed pre-capillary pulmonary hypertension on RHC performed at Assiut University Hospital: mPAP \\> 20 mmHg AND PAWP ≤ 15 mmHg AND PVR ≥ 2 Wood Units.\n\n3-WHO PH Clinical Group 1 (PAH), Group 3 (PH due to lung disease\u002Fhypoxia), or Group 4 (CTEPH \u002F chronic thromboembolic PH) classification assigned by the PH-MDT.\n\n4-Both CTPA and RHC performed within a maximum interval of 4 weeks. b. Exclusion criteria:\n\n1. WHO PH Group 2 (PH due to left heart disease) or Group 5 (PH with unclear\u002Fmultifactorial mechanisms) .\n2. Active malignancy.\n3. Pregnancy, confirmed or suspected.\n4. Contraindication to iodinated contrast agent: eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² OR documented history of severe anaphylactic contrast reaction.\n5. Inability to sustain breath-hold of ≥ 8 seconds (impairs CTPA quality).\n6. Initiation or dose escalation of pulmonary vasodilator therapy (endothelin receptor antagonist, PDE5 inhibitor, soluble guanylate cyclase stimulator, or prostanoid) in the interval between CTPA and RHC, or within 4 weeks prior to CTPA.\n7. Patient refusal to consent or inability to provide informed consent","ALL","18 Years",{"count":18,"type":19},60,"ESTIMATED","OBSERVATIONAL","Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined by a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest, as confirmed by right heart catheterization (RHC) (1). The global prevalence of PH is estimated at approximately 1% of the adult population, rising to 10% or more in individuals over 65 years of age.Pre-capillary pulmonary hypertension, which includes pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), is characterized by a pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and an elevated pulmonary vascular resistance (PVR) ≥2 Wood units (2)\n\nComputed tomography pulmonary angiography (CTPA) is routinely performed in the diagnostic workup of PH and offers a non invasive alternative that can generate multiple quantitative metrics from a single scan (3). Traditional CTPA metrics, including main pulmonary artery diameter (MPAd), the ratio of MPAd to ascending aortic diameter, central pulmonary arteries, and right ventricular to left ventricular diameter (RV\u002FLV ratio) were previously studied in PH patients (4,5,6) Most existing studies have evaluated CTPA metrics in isolation or within single PH subgroups, limiting generalizability across the broader pre-capillary PH population (7).\n\nTherefore, this study aims to systematically investigate the correlation between multiple quantitative CTPA metrics and key invasive hemodynamic parameters derived from RHC in patients with confirmed pre-capillary pulmonary hypertension",[23,24,25,26],"Pulmonary Hypertension","Precapillary Pulmonary Hypertension","Right Heart Catheterisation","CT Angiography",[28],"CTPA and RHC in precapillary PHTN","NOT_YET_RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":19},"2026-06-30",{"date":37,"type":19},"2026-07-30",{"name":39,"class":40},"Assiut University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":20,"phases":4,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100634791","spectral-and-ultra-high-resolution-ct-systems-for-non-invasive-detection-of-myocardial-ischemia-stress-ct-perfusion-vs-ffr-ct-100634791","NCT07544277","Spectral and Ultra High Resolution CT Systems for Non-Invasive Detection of Myocardial Ischemia: Stress CT Perfusion VS. FFR-CT","SURE-CT","Inclusion Criteria:\n\n* Patient referred to our hospitals for elective CCTA for ruling out CAD\n* CCTA evidence of moderate stenosis (50-69%) requiring functional assessment according to ESC guidelines\n\nExclusion Criteria:\n\n* hemodynamically unstable conditions,\n* previous revascularization,\n* myocardial infarction,\n* obesity (BMI\\>40 kg\u002Fm2),\n* renal insufficiency (GFR\\\u003C30 mL\u002Fmin),\n* atrial fibrillation or other significant arrhythmias; and\n* other overt cardiovascular diseases affecting CTP performance (e.g., heart failure, severe valvular regurgitation),\n* pregnancy and breastfeeding,\n* contraindications to iodinated contrast agents or regadenoson.",{"count":50,"type":19},142,"24 Months","Coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide. Coronary Computed Tomography angiography (CCTA) gained a pivotal clinical role for excellent sensitivity in rule-out CAD, but has limited specificity for a tendency to overestimate stenoses and for the lack of information about their hemodynamic impact. Fractional Flow Reserve derived from CT (FFR-CT) and stress CT perfusion (CTP) have been recently proposed to complement CCTA in the non-invasive assessment of myocardial ischemia, increasing the specificity and avoiding unnecessary catheterization. However, on energy-integrating (EID)-CT, FFR-CT has suboptimal performance, while CTP is affected by high radiation exposure. Both these approaches may benefit by the introduction of the new Photon Counting Detector (PCD)-CT technology, but data completely lacks. Aim of the study is to assess the performance of PCD-CT in the identification of significant CAD combining CCTA with FFR-CT and spectral CTP.",[54,26,55,56],"FFR-CT","CT Perfusion","Coronary Arterial Disease (CAD)",[54,58,55,56],"Coronary CT angiography","2026-04-15",{"date":61,"type":33},"2026-04-22",{"date":63,"type":19},"2026-09-01",{"date":65,"type":19},"2029-09-01",{"name":67,"class":40},"IRCCS San Raffaele",2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100580876","serial-coronary-cta-based-plaque-progression-detection-for-management-of-coronary-heart-disease-100580876","NCT06843005","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease: a Randomised Controlled Trial","SUCCESS","Inclusion Criteria:\n\n1. Age between 18 and 80 years old;\n2. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years);\n3. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations.\n\nExclusion Criteria:\n\n1. Patients who have experienced ACS or PCI\u002FCABG;\n2. Patients who have experienced adverse cardiovascular and cerebrovascular events;\n3. Patients who have undergone follow-up CCTA or DSA examinations before enrollment;\n4. Patients with severe hepatic and renal dysfunction;\n5. Patients with contraindications to CCTA examinations;\n6. Patients with poor initial CCTA image quality or data loss.","80 Years",{"count":79,"type":19},3100,"INTERVENTIONAL",[82],"NA","The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.",[85,86,87,26],"Major Adverse Cardiovascular Events (MACE)","Prevention","Coronary Artery Disease(CAD)","RECRUITING","2026-03-19",{"date":91,"type":33},"2026-03-24",{"date":93,"type":33},"2025-02-28",{"date":95,"type":19},"2028-12-30",{"name":97,"class":40},"Zhang longjiang,MD",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":80,"phases":107,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100582456","further-lipid-lowering-with-pcsk9-inhibitors-for-cardiovascular-outcomes-in-high-risk-coronary-plaques-assessed-by-ct-angiography-100582456","NCT06863545","Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography","FLAVOUR IV","Inclusion Criteria:\n\n1. Subject must be ≥ 18 years.\n2. Patients with at least one target lesion meet CCTA-detected plaque features of the following:\n\n   1. Degree of stenosis ≥ 50% or plaque burden ≥ 70%\n   2. At least 2 of the following high-risk plaque features:\n\n   i. Low-attenuation plaque ii. Positive remodeling iii. Napkin-ring sign iv. Spotty calcium\n3. The target lesion is located at the proximal or mid segment of left anterior descending artery, left circumflex artery or right coronary artery.\n4. Subject is able to confirm his\u002Fher understanding of the risks, benefits, and treatment alternatives of receiving study-related treatment. He\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study-related procedure.\n\nExclusion Criteria:\n\n1. Target lesions underwent or planned to revascularization.\n2. Patients with acute coronary syndrome.\n3. New York Heart Association class III or IV, or last known left ventricular ejection fraction \\\u003C 30%.\n4. Uncontrolled or recurrent ventricular tachycardia.\n5. Homozygous familial hypercholesterolemia.\n6. Active liver disease or hepatic dysfunction.\n7. Failed CCTA plaque analysis.\n8. Non-cardiac co-morbid conditions with life expectancy \\\u003C 2 years.\n9. Pregnant and\u002For lactating women.\n10. Known hypersensitivity or contraindication to statin or PCSK9 inhibitors.",{"count":106,"type":19},3596,[82],"The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography (CCTA)-detected high-risk plaques.",[110,26,111,112],"Coronary Artery Disease","PCSK9","Cardiovascular Events",[114,115,116,58],"PCSK9 inhibitors","Lipid-lowering therapy","High-Risk Coronary Plaques","2026-02-03",{"date":119,"type":33},"2026-02-06",{"date":121,"type":33},"2025-04-22",{"date":123,"type":19},"2033-04",{"name":125,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University",6,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":80,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100525215","ideal-study-blinded-rct-for-the-impact-of-ai-model-for-cerebral-aneurysms-detection-on-patients-diagnosis-and-outcomes-100525215","NCT06118840","IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes","Assessing the Impact of an Artificial Intelligence-Based Model for Intracranial Aneurysm Detection in CT Angiography on Patients' Diagnosis and Outcomes: The IDEAL Study - A Web-Based Multicenter, Double-Blinded Randomized Controlled Trial","IDEAL","Inclusion Criteria:\n\n* Adult inpatients and outpatients who are scheduled for head CTA scanning.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Patients with contraindications to CTA.\n* Modified Rankin Scale (mRS) score \\> 3.\n* Refuse to sign informed consent.\n* Participation in other clinical studies of intracranial aneurysms.\n* Patients with failed head CTA scanning or incomplete image data, or poor image quality.",true,{"count":137,"type":19},6450,[82],"This study (IEDAL study) intends to prospectively enroll more than 6450 patients who will undergo head CT angiography (CTA) scanning in the outpatient clinic. It will be carried out in 21 hospitals in more than 10 provinces in China. The patient's head CTA images will be randomly assigned to the True-AI and Sham-AI group with a ratio of 1:1, and the patients and radiologists are unaware of the allocation. The primary outcomes are sensitivity and specificity of detecting intracranial aneurysms. The secondary outcomes focus on the prognosis and outcomes of the patients.",[141,26,142,143],"Intracranial Aneurysm","Deep Learning","Double Bind Interaction","2025-10-01",{"date":146,"type":33},"2025-10-07",{"date":148,"type":33},"2024-05-20",{"date":150,"type":19},"2026-12",{"name":152,"class":40},"Jinling Hospital, China",21,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":135,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":80,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100602523","stepped-wedge-cluster-randomized-trial-of-ai-assisted-cta-detection-for-intracranial-aneurysms-in-regional-hospitals-100602523","NCT07124624","Stepped-Wedge Cluster Randomized Trial of AI-Assisted CTA Detection for Intracranial Aneurysms in Regional Hospitals","Impact of an AI-Driven CT Angiography Model on Intracranial Aneurysm Detection and Clinical Outcomes in Regional Hospitals (IDEAL2): A Nationwide Stepped-Wedge Cluster-Randomized Trial","IDEAL2","Inclusion Criteria:\n\n-Patients in the outpatient setting who are scheduled to undergo head CTA scanning\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* History of cerebrovascular surgery involving any metallic implants (e.g., aneurysm embolization, aneurysm clipping, or vascular stenting)\n* Modified Rankin Scale (mRS) score \\> 3\n* Refuse to sign written informed consent\n* Contraindications to CTA examination\n* CTA scan failure, incomplete imaging data, or image quality insufficient for diagnostic evaluation",{"count":163,"type":19},14400,[82],"This study (IDEAL 2) is a nationwide stepped-wedge cluster-randomized trial designed to prospectively enroll over 14,400 patients undergoing outpatient head CT angiography (CTA). The trial will be conducted across more than 72 regional hospitals in China. Clusters were randomly assigned to nine randomization groups. In accordance with the stepped-wedge design, clusters will sequentially transition from the control condition (standard human diagnosis) to the intervention condition (AI-assisted diagnosis) at regular intervals over a 10-month period, until all clusters receive the intervention. The primary outcome is the detection rate of intracranial aneurysms. Secondary outcomes include patient prognosis and clinical outcomes.",[141,26,167,168],"AI (Artificial Intelligence)","Cluster Randomized Trial",[170,167,171],"Intracranial aneurysm","Stepped-wedge cluster-randomized trial","2025-08-15",{"date":174,"type":33},"2025-08-20",{"date":176,"type":19},"2025-10-09",{"date":178,"type":19},"2029-08-31",{"name":152,"class":40},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":80,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":68},"100565686","ai-driven-cta-reconstruction-for-intracranial-lvo-100565686","NCT06645405","AI-Driven CTA Reconstruction for Intracranial LVO","Segmentation and Modeling for Accurate Reconstruction of CT Angiography of Intracranial Large Vessel Occlusion with Artificial Intelligence: a Stepped-wedge, Cluster-randomized Controlled Trial","SMART-AI","Inclusion Criteria:\n\n1. Male or Female, 18 years of age or older.\n2. Patients who present with signs and\u002For symptoms concerning acute ischemic stroke.\n3. Patients who undergo noncontrast CT and CT angiography imaging.\n4. Patients determined to have an intracranial large vessel occlusion (including the internal carotid artery, middle cerebral artery M1 segment, and M2 segment), and eligible for endovascular treatment.\n\nExclusion Criteria\n\n1\\) CT imaging with severe motion artifacts.","95 Years",{"count":190,"type":19},174,[82],"Acute ischemic stroke (AIS) caused by intracranial large vessel occlusion (LVO) in the anterior circulation significantly contributes to stroke-related disability and mortality. Recent randomized controlled trials have demonstrated substantial benefits of endovascular thrombectomy (EVT) when patients are appropriately triaged beforehand. However, accurately orienting the 'missed segment' during EVT remains challenging. Guide-wires often fail to navigate through the occlusion or are mistakenly directed into the small tranches or even cause vessel rupture. To address this clinical need, the investigators developed an artificial intelligence (AI) algorithm to automate the reconstruction of CT angiography (CTA), focusing on the occluded LVO segment. To evaluate the clinical utility of this AI algorithm, the investigators propose a prospective, stepped-wedge cluster-randomized study to determine whether integrating our AI algorithm into AIS care flow can reduce the time for first pass of the thrombus by improving the visualization of the occluded segment on CTA. Physicians will assess patient eligibility for thrombectomy, and all selected patients will receive standard care according to current guidelines. This approach is expected to enhance patient treatment outcomes for endovascular thrombectomy by leveraging readily available data.",[194,195,196,26],"Acute Ischemic Stroke","Artificial Intelligence (AI)","Endovascular Thrombectomy","2024-10-15",{"date":199,"type":33},"2024-10-16",{"date":201,"type":19},"2024-10-20",{"date":203,"type":19},"2025-12-31",{"name":205,"class":40},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital"]